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Prophylactic perioperative cefuroxime
levels in plasma and adipose tissue at the
time of caesarean section (C-LACE): a
protocol for a pilot experimental,
prospective study with non-probability
sampling to determine interpatient
variability
Hanadi H. Alrammaal1,2*, Hannah K. Batchelor1,3, Hsu P. Chong4,5, Victoria Hodgetts Morton5,6 and R. Katie Morris5,6
Abstract
Background: The aim of the C-LACE study is to measure cefuroxime concentration in plasma and adipose tissue of
non-obese and obese pregnant women undergoing caesarean section.
Methods: This study plans to compare maternal cefuroxime concentrations (plasma and adipose tissue), at the
time of skin incision and time of skin closure during a caesarean section from non-obese (body mass index BMI <
30 kg/m2) and obese (BMI ≥ 30 kg/m2) pregnant women. The incidence of post-surgical site infection will also be
measured. At least 15 participants are required for each arm (non-obese vs obese) with a total of 30 participants.
The study participants will be followed up between 30 and 40 days post-caesarean section to record details of any
post-caesarean surgical infection to explore correlations between BMI, measured cefuroxime concentrations and
post-caesarean infection rates.
Discussion: This pilot study will allow the development of a model testing the inter-patient variability in plasma
and adipose tissue concentrations of cefuroxime. The results will facilitate the development of a larger study to
determine whether differences in cefuroxime plasma and tissue concentration in obese and non-obese women can
support the development of a physiologically based pharmacokinetic model. This model can then be used to
propose dosing adjustments that can be used in a further trial to optimise cefuroxime dosing for women
undergoing caesarean section.
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Administrative information
This protocol follows the SPIRIT checklist (items of the
checklist are numbered in curly brackets).
Background {6a}
The prevalence of obesity in pregnant women in Eng-
land at the time of booking a caesarean section (CS) has
been reported to be 16% [1, 2]. One complication of
obesity in pregnancy relates to the requirement for op-
erative delivery, i.e. CS. The rate of CS in an obese (Body
Mass Index BMI ≥ 30 kg/m2) pregnant population is
33.8% [3]. The rate of post-CS infection is higher
amongst obese pregnant women compared to those who
are not obese; the adjusted odds ratio of surgical site in-
fection in an obese population was reported to be 2.41
(95% CI 1.73–3.37) [4]. Prophylactic single dose peri-
operative intravenous (IV) antibiotic is recommended
for CS; and several studies have examined the use of al-
ternative antibiotics, with cefazolin being the most com-
monly used in the USA and cefuroxime in the UK.
Numerous studies have focussed on the use of cefazolin
in obese patients undergoing CS to gain an understand-
ing of optimal dosing and clinical outcomes [5]. Several
studies proposed an increased dose of cefazolin (3 g)
compared to the standard dose (2 g) for obese pregnant
women to achieve sufficient antibiotic levels during CS
[6–8]. It was postulated by Holt et al. (in 1994) that
doses of cefuroxime up to 1500 mg may not achieve suf-
ficient minimum inhibitory concentration (MIC) for
most of the common bacteria in maternal blood during
CS [9]. Sub-therapeutic antibiotic concentration is a cru-
cial factor in global bacterial resistance. It is essential
that the therapeutic concentration of antibiotic is
achieved in both maternal blood and at the site of inci-
sion during CS for effective therapy. No study to date
has measured cefuroxime concentrations in blood and
adipose tissue in obese pregnant women undergoing CS
[10]. Thus, a study to explore the drug concentration in
this population at the time of CS is essential. This study
will analyse cefuroxime concentration in plasma and
adipose tissue samples to accurately measure levels
achieved in non-obese and obese pregnant women
undergoing CS to confirm if therapeutical cefuroxime
levels are reached in plasma and adipose tissue. Further,
to use the measured cefuroxime concentrations to verify
a physiologically based pharmacokinetic (PBPK) model
of cefuroxime in CS to explore the impact of (i) dose
and (ii) BMI post-administration of cefuroxime on both
blood and tissue cefuroxime concentrations in an obese
population and suggest a dose adjustment if required
and applicable.
Objectives {7}
The main objective of conducting this pilot and feasibility
study is to assess the process and protocol of recruiting
patients, sample collection, follow-up and procedure of C-
LACE. Also to gain an understanding of cefuroxime con-
centrations in normal-body weight pregnant vs. obese
pregnant women. The primary objective is to measure the
concentration of cefuroxime in the collected blood and
tissue samples using an appropriate analytical method and
to assess whether cefuroxime administered provides con-
centrations above the MIC in both the blood and adipose
tissue for all patients regardless of their BMI. Additionally,
to assess whether there are differences in cefuroxime con-
centrations from obese vs non-obese women.
Trial design {8}




To measure cefuroxime concentration in plasma and adi-
pose tissue (within the incision) at time of skin incision
and skin closure in obese and non-obese pregnant patients
requiring CS. Moreover, to explore the relationship be-
tween the dose of cefuroxime administered and concen-
tration measured in both blood and adipose tissue with
respect to BMI of the patient. To measure the incidence
of post-CS infections in obese and non-obese pregnant
women at 30–40 days post-CS; and to assess if the rate of
infection is correlated with BMI, dose administered and
cefuroxime blood or adipose tissue concentrations.
Cefuroxime is administrated to pregnant women under-
going CS as per Birmingham Women’s Hospital protocol;
i.e. IV infusion 30–60 min before skin incision.
Outcomes {12}
Outcomes of C-LACE pilot and feasibility study are AS
FOLLOWS:
 Patients’ recruitment rate
 Collecting samples strategies
 Analytical method for sample analysis
 Data collection and forms completion
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 Follow-up and participants’ retention
Part A: Cefuroxime levels in plasma and adipose tissue
The minimum inhibitory concentration is not harmo-
nised between guidelines; thus, the time above the mini-
mum inhibitory concentration (T>MIC) will be reported
for MIC values of 1, 4 and 8 mg/L [5, 11] as these values
correlate to the most common bacteria involves in post-
CS surgical infections (Table 1).
Part B: Surgical site infection
The rate of surgical site infection will be reported in
non-obese and obese pregnant women undergoing CS.
This study will follow the definition of surgical infection
as per the definitions set out by the US Centre’s for Dis-
ease Control and Prevention (Centre’s for Disease Con-
trol and Prevention 2019) [14].
Target population
The target population are non-obese and obese pregnant




 Pregnant women 18 to 50 years old, with a singleton
pregnancy undergoing elective CS at 37 weeks or
over.
 Participant is able to give consent and agree to
sample storage.
 Participant agrees to be contacted for follow-up.
 Participant contributing to the study needs to be
able to read and/or understand English.
Exclusion criteria
 Multiple pregnancy
 Previous CS that resulted in a surgical site infection
 Emergency CS
 Any non-elective CS including those requiring early
delivery without threat to maternal or foetal health
that were not previously planned.
 Body mass index (BMI) less than 18 kg/m2 or
greater than or equal to 45 kg/m2 (at time of first
pregnancy appointment and at time of delivery).
 Currently enrolled in a randomized controlled trial
for an intervention to reduce post-operative surgical
site infection
 Diabetes (type 1, type 2 or gestational)
 Hypertension
 Renal disease
 Cardiovascular disease (e.g. maternal structural
cardiac disease)
 Liver disease
 Inflammatory bowel disease (e.g. Crohn’s disease or
ulcerative colitis)
 Cephalosporin or penicillin allergy
 Administration of antibiotic within 1 week prior to
delivery
 Suspected pre-existing infection (including
chorioamnionitis)
 Autoimmune disease (e.g. systemic lupus
erythematosus, rheumatoid arthritis)
 Chronic use of corticosteroid
 History of wound breakdown in an abdominal
surgery
 Prior laparotomy for any indication (e.g. previous
ovarian cystectomy or previous bowel surgery)
Table 1 Most common bacteria causative of infection post-caesarean section and the minimum inhibitory concentration range/
breakpoint
Microorganism MIC range/breakpoint (mg/L) [5, 11–13]









Other organisms Raoultella ornithinolytica 0.001–8
Morganella morganii ND
ND Not determined
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Setting {9}
This single-centre study will take place at Birmingham
Women’s Hospital which is a large teaching hospital that
is part of Birmingham Women’s and Children’s Hospital
NHS Foundation Trust.
Participant selection and enrolment
Any patient (18–50 years) who requires a CS as part of
their clinical care will be screened for inclusion. The po-
tential participants will be identified using hospital clin-
ical lists, where lists relate to a pre-booked CS a Good
Clinical Practice (GCP) trained research midwife who is
a member of the clinical care team will assess the eligi-
bility of patients to participate in the study according to
inclusion/exclusion criteria using screening form. The
woman will then be provided with the participant infor-
mation sheet at this meeting by the research midwife. In
addition, if a pregnant woman is booked for CS at a
meeting they may be informed about the study by a re-
search midwife or their clinical care team and provided
with a participant information sheet. The participants
will receive information about the study well in advance
(at prior clinic appointments) and at least 24 hours prior
to CS so that all participants have sufficient time to con-
sider taking part.
This study plans to compare data from obese (BMI ≥
30 kg/m2) and non-obese women (BMI < 30 kg/m2) at
the time of booking (10–14 weeks of pregnancy). At
least 15 participants are required for each arm with a
total of 30 participants. The study sequence is sum-
marised in Table 2.
Screening for eligibility and recruitment {15}
A GCP trained research midwife will assess the eligibility
of patients to participate in the study according to inclu-
sion/exclusion criteria using screening form.
Ineligible and non-recruited participants
Certain ineligible are stated in the exclusion criteria. Re-
search midwives/clinician will review and reassess each
potential participant and confirm eligibility of patients to
participate in the study at the day of CS.
Patient consent {26a}
A suitably qualified research midwife or doctor who is
also part of the clinical care team will introduce the
study to the woman at their pre-operative assessment. A
participant information sheet (PIS) will be provided to
facilitate this process. Investigators will ensure that they
adequately explain the aim, anticipated benefits and po-
tential hazards of taking part in the trial to the woman.
They will also stress that participation is voluntary and
that the woman is free to refuse to take part and may
withdraw from the trial at any time. The woman will be
given adequate time to read the PIS and to discuss their
potential participation and be given the opportunity to
ask questions. If the woman expresses an interest in par-
ticipating in the trial, they will be asked to sign and date
the latest version of the informed consent form at least
24 h prior to CS. The woman will be asked for her con-
sent to withdraw 3 blood samples (with a maximum vol-
ume of 10 mL blood per sample) and 2 fat tissues and
for collection of outcome data from their medical re-
cords and a telephone interview at 30–40 days post-
natal that will take approximately 5–15 min.
Withdrawal of study participants
Each participant has the right to withdraw from the
study at any time and this will not affect their clinical
care. In addition, the investigator may discontinue a par-
ticipant from the study at any time if the investigator
considers it necessary for any reason including the
following:
 Ineligibility (either arising during the study or
retrospectively having been overlooked at screening)
 Withdrawal of consent
Withdrawal from the study will result in the exclusion
of the data for that participant from analysis; provided




Clinic list will be reviewed for eligible participants using the screening form
On the day of caesarean
section
A Venflon cannula will be inserted into the woman as part of the research process to enable withdrawal of the
required blood samples without the need for additional needles. This second access point will ensure that the blood
sampling is minimally disruptive to the CS procedure.
At 30–40 days post-
caesarean section
Participant’s medical file and notes will be reviewed by the research midwife to identify any post-surgical site infection
which will be recorded on the 6-week outcome form. Research midwife will attempt to contact the participant 3
times between 30 and 40 days post-CS to complete the follow-up interview form.
Samples analysis Blood and adipose tissue will be analysed by LC-MS/MS [15]
GCP Good Clinical Practice, CS Caesarean section, LC-MS/MS liquid Chromatography with tandem mass spectrometry
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that the withdrawal occurs within 3 months of data
collection.
Study assessments {13}
The study assessment and paperwork associated are
summarised in Table 3 (forms are in the online supple-
mentary file).
Data collection methods {18a}
Background information will be collected from each par-
ticipant using the baseline form. This information is re-
quired for interpretation of the data and dissemination.
Following the collection of the data from all forms
(screening, consent, baseline, eligibility reassessment, op-
eration, discharge, follow-up interview, 6-week record
check) will be filled, signed and shared via the secure
system; this system can be accessed at the university and
the hospital and ensures the security of data, any data,
entered will be anonymised.
The study has two parts: part A, which is blood and
adipose tissue sampling for cefuroxime concentrations;
part B, is a follow-up of patients’ post-partum at be-
tween 30 and 40 days to record the incidence of post-
surgical infection.
Part A: Sample collection at caesarean section
The clinical care team will record the time of cefuroxime
administration, dose administered, type of anaesthesia
used, blood loss and other relevant clinical information.
Five samples will be collected: 1 blood sample at time of
skin incision, 1 blood sample at time of skin closure, 1
blood sample at recovery room (< 3 h following CS), 1 adi-
pose tissue sample (approximately 1 cm from the skin in
the middle of the Pfannesnstiel or vertical midline inci-
sion) at skin incision and one adipose tissue sample (from
a similar location to sample 1) just prior to skin closure.
Blood sample and adipose tissue analysis
The concentration of cefuroxime in blood and adipose
tissue will be quantified using standard laboratory
methods [15].
Part B: Follow-up for post-surgical infection
At between 30 and 40 days post-CS, the study partici-
pants will be contacted by telephone by a research
nurse/midwife from the research team and a review will
be made to record any type of post-surgical infection.
The follow-up interview form will be used to record the
details of any infection reported. If the participant
attended to the hospital for a post-natal appointment at
30–40 days, the interview can be conducted at that time
to minimise the burden to the participant.
Plans to promote participant retention and complete
follow-up {18b}
Patient medical notes will be reviewed by a member of
the clinical care team using the 30–40 days outcome
form to identify whether there has been a reported post-
surgical infection. Post-surgical infection is defined as
per the definitions set out by the US Centre’s for Disease
Control and Prevention [14].
Data management {19} and confidentiality {27}
All participants will be given a study ID upon recruit-
ment to the study. A spreadsheet that links study ID to
patient ID will be held at Birmingham Women’s and
Children’s Hospital NHS Foundation Trust under the
control of the local PI. This information will be pass-
word protected and stored on an encrypted computer
that conforms to the standard NHS security
requirements.
The study ID will be used on all forms; this information
provides anonymised data to the University of Birming-
ham that no longer has any personal identifiable data. Fol-
lowing collection the data from all forms will be entered
on a secure system at the NHS site (undertaken by the re-
search midwife); this system can be accessed at the univer-
sity and ensures anonymity for the participants.
All processes will be carried out with respect to par-
ticipant confidentiality. All participant data will be anon-
ymised by being replaced with a study ID number prior
to data sharing with the University of Birmingham. The
anonymity code will only be known to the local site PI
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and associated research nurse/midwife team. The data
will be controlled by usernames and encrypted
passwords.
Statistics {20a}, sample size {14} and study assessment
There is no predefined sample size yet sufficient num-
bers are required to provide an estimate of average
values as well as the level of inter-patient variability. Pre-
vious work to measure the concentration of antibiotics
in plasma and in tissue in obese and non-obese pregnant
women following CS has used sample sizes of 14 in each
arm to detect differences in adipose antibiotic concen-
tration [16, 17]. Therefore, in this study, we plan to re-
cruit 15 women in each arm (BMI < 30 kg/m2 and BMI
≥ 30 kg/m2). The BMI measurements will be taken from
the women at their time of booking appointment which
occurs between 10 and 14 weeks of pregnancy. The BMI
of participants immediately prior to CS will be deter-
mined to review any major changes during their preg-
nancy which may affect the results, for example, a
change from < 30 kg/m2 to an extremely obese partici-
pant at CS.
The differences in mean concentration values in
plasma and adipose tissue between the obese and non-
obese populations will be compared using ANOVA ana-
lysis to determine whether there are significant differ-
ences. SPSS software will be used for all statistical
analysis. The rate and type of infection will be analysed.
The rate of infections will be analysed in correlation
with (1) dose administered, (2) BMI and (3) cefuroxime
concentrations at both sites at the time of skin incision
and skin closure.
Success criteria and assessment of C-LACE pilot and
feasibility study
These criteria applied to participants consented and did
not withdraw from the study at any time-point of C-
LACE study:
 Patients’ recruitment rate: as per Birmingham
Women’s Hospital Caesarean Section rate,
recruitment of 30 patients would be achievable
easily within 3 months. If this was not achieved, the
protocol (specific inclusion and exclusion criteria)
would be reviewed and reassessed.
 Collecting samples: this pilot and feasibility study
would be considered successful if plasma and
adipose tissue samples at the time of incision and
time of closure and plasma sample at time of
recovery were successfully collected for ≥ 75% of
participant in each arm. If this was not achievable,
the sampling strategies will be revised and
reassessed.
 Sample analysis: this pilot and feasibility study would
be considered successful if ≥ 80% of plasma and
adipose tissue samples collected were successfully
analysed via the analytical method described; If not,
sampling handling, transferring and sample analysis
protocol will be revised and reassessed.
 Data collecting: this pilot and feasibility study would
be considered successful if ≥ 80% of data collecting
forms was fulfilled for each participant; if not,
logistics and study procedure of C-LACE study will
be revised at Birmingham Women’s Hospital.
 Follow-up: the described follow-up protocol will be
considered successful if participants’ retention were
≥ 80%. The participant will be considered as lost to
follow-up, if the participant could not be contacted
and the patients file and notes were not reviewed.
Analysis and sub-analysis of outcomes and success cri-
teria of C-LACE pilot and feasibility study will be made
to explore the reasons of unsuccessful.
Missing data and lost to follow-up {20C}
Every attempt will be made to collect full follow-up data
for all study participants; it is thus anticipated that miss-
ing data will be minimal. The main analysis will use
available data only; however, the amount of missing data
will be assessed, and if necessary, sensitivity analyses will
be undertaken. If the participant could not be contacted,
but the patients’ medical records and notes were
reviewed, the participant will be considered enrolled in
the follow-up. The patient will be considered as lost to
follow-up, if the participant could not be contacted and
the patients’ file and notes were not reviewed.
Data monitoring {21a}
The study may be monitored or audited in accordance
with the current approved protocol, GCP, relevant regu-
lations and standard operating procedures. This study
does not include blinding and patients are following the
standard clinical pathway where the only intervention is
the taking of adipose tissue and plasma samples there-
fore a data monitoring committee is not required.
Access to data {29}
All data will be collected only after the participant
freely gave written consent to process their data in
accordance with GDPR (this consent in included
within the consent form for the study). Direct access
to shared secure system will be granted to authorised
representatives from the Sponsor and host institution
for monitoring and/or audit of the study to ensure
compliance with regulations.
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Harms {22}
The research protocol does not expose the participants
to any risks as the study does not affect their clinical
treatment. The collection of additional blood samples
and adipose tissue samples during CS are the only add-
itional study-specific procedures. These additional blood
samples will be taken by a clinical member of the re-
search team trained in phlebotomy. There is a consent
request for these study-specific procedures to minimise
the changes to routine clinical care and reduce the bur-
den to participants. The risks associated with this re-
search are minimal to participants.
All participants will be contacted at 30–40 days fol-
lowing CS to ask about post-surgical infections; this will
not affect their clinical care in any way and does not
pose any risks to participants.
Provisions for post-trial care {30}
Participants within this trial will follow standard clinical
procedures with the intervention being taking plasma and
adipose tissues samples thus there is no specific post-trial
care. As the participants are NHS patients, indemnity is
provided through the NHS schemes. The University of
Birmingham provides clinical research insurance for stud-
ies that it sponsors. This insurance is provided via mem-
bership of UMAL.
Auditing {23}
The study may be monitored, or audited in accordance
with the current approved protocol, GCP, relevant regu-
lations and standard operating procedures.
Protocol amendments {25}
The Investigator will submit and, where necessary, ob-
tain approval from the Health Research Authority
(HRA) and Health and Care Research Wales (HCRW)
for all substantial amendments to the original approved
documents.
Discussion
Interpatient pharmacokinetic variability of cefuroxime
Due to the great variability associated with pharmacoki-
netic measurements, the use of PBPK modelling is a
common tool to understand the distribution of drugs.
Specialist software packages are available that include
details on pregnant population characteristics. SimCYP
software will be used to model the blood and adipose
concentrations of cefuroxime and to compare this mod-
elled data to the experimental results from the C-LACE
study. It is anticipated that this clinical data coupled
with PBPK models will inform any future changes to
doses of cefuroxime used for CS, particularly in relation
to obese women.
Definition of the end of study
The end of study is the date at which the follow-up
interview is conducted at 30–40 days following CS. This
is where the follow-up ends for all participants.
Patient and public involvement
A similar study conducted by Victoria Hodgetts Morton
and Katie Morris (PREPS trial) involved the public and
patients; those involved were supportive of any research
undertaken to minimise the risks of post-surgical infec-
tions following CS [18]. Informal discussions about this
study with women who have had CS have all been posi-
tive as the burden of participation is minimised where
possible.
Ethics and dissemination {31a-b-c}
Results of this trial will be submitted for publication in a
peer-reviewed journal. The manuscript will be prepared
by HHA and HKB with contributions from the local PI
(RKM) and the local researcher (VHM) and authorship
will be determined by mutual agreement. Authors must
acknowledge that the trial was performed with the sup-
port of the Saudi Arabian Government. Currently, there
are no plans for granting public access to the full proto-
col, participant-level dataset and statistical code.
Provenance and peer review
The protocol has been peer-reviewed within the research
team and by the research and governance team at the
University of Birmingham as part of the agreement to
sponsor the study and by the University of Birmingham’s
Clinical Research Compliance Team (CRCT). Further,
this protocol has been reviewed and approved by HRA
and HCRW.
Trial status
Ethical approval is granted (C-LACE protocol v0.4, 02
January 2020); the anticipated date of recruitment was
1st of September 2020; requirement expected to be com-
pleted on 1st of December 2020). This study was delayed
due to COVID-19 epidemic.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s40814-021-00794-3.
Additional file 1.
Additional file 2. C-LACE Screening Form.
Additional file 3. SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*.
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